Kura Oncology, Inc.
About Kura Oncology, Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $67.5M
- Net income
- -$278.7M
- Total assets
- $738.4M
- Market cap
- $775.9M
- Operating margin
- -449.9%
- Net margin
- -412.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $67.5M
- Operating expenses
- $371.1M
- Operating income
- -$303.6M
- Income tax
- $297.0K
- Net income
- -$278.7M
- EPS (basic)
- $-3.18
- EPS (diluted)
- $-3.18
Balance sheet
- Total assets
- $738.4M
- Current assets
- $708.7M
- Total liabilities
- $564.2M
- Current liabilities
- $117.0M
- Shareholders’ equity
- $174.1M
Cash flow
- Operating cash flow
- -$64.1M
- Investing cash flow
- -$13.1M
- Financing cash flow
- $1.8M
- Net cash flow
- -$75.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $775.9M
- EPS (diluted)
- $-3.18
- Shares outstanding
- 90.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 25, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $278.7M in FY2025.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Kura Oncology, Inc..
Write a review
News about Kura Oncology, Inc.
News & sentiment via Polygon.io
